000100 on Korean Stock Exchange
Yuhan
Logo: Yuhan Corporation, Public domain, via Wikimedia Commons3
South Korean pharmaceutical company
Yuhan Corporation (Korean: 주식회사 유한양행; Hanja: 株式會社 柳韓洋行; RR: Jusik Hoesa Yuhan Yanghaeng) is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962. Yuhan is one of the top Korean pharmaceutical companies, along with Celltrion, Samsung Biologics, GC Pharma, and Hanmi Pharmaceutical.2 It was founded by Ilhan New.1 Its shares trade on Korean Stock Exchange under the symbol 000100.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
Overview
- Ticker000100 on Korean Stock Exchange1
- Industrypharmaceutical industry1
- HeadquartersSeoul1
- Websitewww.yuhan.co.kr
- Legal formjusik hoesa1
See how the biggest companies compare on our leaderboards
Yuhan Corporation (Korean: 주식회사 유한양행; Hanja: 株式會社 柳韓洋行; RR: Jusik Hoesa Yuhan Yanghaeng) is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962. Yuhan is one of the top Korean pharmaceutical companies, along with Celltrion, Samsung Biologics, GC Pharma, and Hanmi Pharmaceutical.2
Leadership
Who has led Yuhan, and when. Pick a name to see everywhere that person has worked.
Products and brands
Yuhan Brands
Pharmaceutical
Non-Pharm/Medical Care
Health Food
Dental/Tooth Care
Read the full text
Chemical Cosmetic
Living Product
Animal Pharmaceuticals
Other Brands
Arm & Hammer
From Wikipedia’s article on Yuhan, shared under CC BY-SA 4.0.4
Timeline
Calendar
Drug trials and FDA: coming up
- Jun 19, 2027Phase 2 trial readout expected Phase 2 trial of Lesigercept in Allergic Diseases: primary completion expected Jun 19, 2027 (ClinicalTrials.gov NCT07415551).5
- Jun 2027Phase 1/2 trial readout expected Phase 1/2 trial of YH32364 in EGFR Overexpression: primary completion expected Jun 2027 (ClinicalTrials.gov NCT06975410).6
Drug trials and FDA: recently
- Jan 15, 2026Phase 3 trial completed Phase 3 trial of YHP2401, YHR2402 and others in Acute Bronchitis: primary completion Jan 15, 2026, no results posted yet (ClinicalTrials.gov NCT07111468).7
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Links
- Websitewww.yuhan.co.kr1
- WikipediaYuhan
- More imagesWikimedia Commons
- WikidataQ8060442
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataYuhan on Wikidata
- 2WikipediaYuhan on Wikipedia
- 3Wikimedia CommonsYuhan logo by Yuhan Corporation, Public domain
- 4WikipediaYuhan on Wikipedia (revision used)
- 5
- 6
- 7